This interpretation is supported by recently published in vitro data where treatment of two prostate cancer cell lines with either abiraterone or enzalutamide increased the expression of constitutively active AR-Vs (AR-V7 and AR-V567es) [16]. This evidence concerns the gene AR and prostate carcinoma.